ES2054806T3 - Cicloalquilamidas de (8beta)-1-alquil-6-(sustituido)-ergolinas. - Google Patents

Cicloalquilamidas de (8beta)-1-alquil-6-(sustituido)-ergolinas.

Info

Publication number
ES2054806T3
ES2054806T3 ES88305408T ES88305408T ES2054806T3 ES 2054806 T3 ES2054806 T3 ES 2054806T3 ES 88305408 T ES88305408 T ES 88305408T ES 88305408 T ES88305408 T ES 88305408T ES 2054806 T3 ES2054806 T3 ES 2054806T3
Authority
ES
Spain
Prior art keywords
alkyl
substituted
ergolins
cyclloalkylamides
8beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88305408T
Other languages
English (en)
Inventor
Mark M Foreman
William L Garbrecht
Gifford P Marzoni
Kathleen R Whitten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2054806T3 publication Critical patent/ES2054806T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

ESTA INVENCION FACILITA (8 BETA)-1-ALQUIL-6-ERGOLINAS (SUSTITUIDA)-8-CARBOXAMIDAS DE LA FORMULA (I) DONDE R1 ES ALQUILO C1-C4; R2 ES ARILO O ALQUILO C1-C4 DE CADENA LINEAL; R3 ES HIDROGENO O ALQUILO C1-C4 DE CADENA LINEAL; R4 ES HIDROGENO, ALQUILO C1-C4, HIDROXI O ALCOXI C1-C4, M ES 0,1,2 O 3 O UNA SAL FARMACEUTICAMENTE ACEPTABLE DELOS MISMOS. LOS COMPUESTOS SON UTILES PARA BLOQUEAR LOS RECEPTORES 5HT2 DE LOS MAMIFEROS QUE TENGAN UN EXCESO DE SEROTINA CENTRAL O PERIFERICA.
ES88305408T 1987-06-15 1988-06-14 Cicloalquilamidas de (8beta)-1-alquil-6-(sustituido)-ergolinas. Expired - Lifetime ES2054806T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6228587A 1987-06-15 1987-06-15

Publications (1)

Publication Number Publication Date
ES2054806T3 true ES2054806T3 (es) 1994-08-16

Family

ID=22041482

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88305408T Expired - Lifetime ES2054806T3 (es) 1987-06-15 1988-06-14 Cicloalquilamidas de (8beta)-1-alquil-6-(sustituido)-ergolinas.

Country Status (22)

Country Link
EP (1) EP0296748B1 (es)
JP (1) JP2653835B2 (es)
KR (1) KR960010454B1 (es)
CN (1) CN1019451B (es)
AT (1) ATE87921T1 (es)
AU (1) AU613641B2 (es)
CA (1) CA1339661C (es)
DE (1) DE3880022T2 (es)
DK (1) DK322588A (es)
EG (1) EG18586A (es)
ES (1) ES2054806T3 (es)
HK (1) HK77693A (es)
HU (2) HU203344B (es)
IE (1) IE61884B1 (es)
IL (1) IL86725A (es)
MX (1) MX11866A (es)
NZ (1) NZ225022A (es)
PH (1) PH24309A (es)
PT (1) PT87716B (es)
SU (1) SU1597103A3 (es)
UA (1) UA6022A1 (es)
ZA (1) ZA884222B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902691A (en) * 1988-12-19 1990-02-20 Eli Lilly And Company Heteroalkylamides of (8-β)-1-alkyl-6-(substituted)ergolines useful for blocking 5HT2 receptors
IT1232692B (it) * 1989-08-04 1992-03-04 Poli Ind Chimica Spa Derivati ergolinici con attivita' dopaminergica
US5043341A (en) * 1990-04-11 1991-08-27 Eli Lilly And Company N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides
US5141944A (en) * 1990-04-11 1992-08-25 Eli Lilly And Company N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides
JPH11503757A (ja) * 1995-04-18 1999-03-30 イーライ・リリー・アンド・カンパニー ５−ｈｔ▲下７▼レセプターにおいて生理学的および病理学的機能を生じるエルゴリン化合物の使用方法
US5880134A (en) * 1996-03-20 1999-03-09 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor
EP0961148B1 (en) 1998-05-26 2010-07-21 Canon Kabushiki Kaisha Camera with focus detecting device
EP2515654A4 (en) 2009-12-23 2013-04-24 Map Pharmaceuticals Inc NEW ERGOLINANALOGA
CN102775402B (zh) * 2011-05-13 2015-08-26 上海现代制药股份有限公司 一种制备二氢麦角酸的中间体及其制备方法
KR20140042868A (ko) 2011-06-23 2014-04-07 맵 파마슈티컬스, 인코포레이티드 신규한 플루오로에르골린 유사체
EP2793580A4 (en) 2011-12-19 2015-05-20 Map Pharmaceuticals Inc NEW DERIVATIVES OF ISO-ERGOLINE
AU2012355983A1 (en) 2011-12-21 2015-01-22 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH386441A (de) * 1961-02-17 1965-01-15 Sandoz Ag Verfahren zur Herstellung von am Indolstickstoff substituierten Derivaten der Lysergsäure-Reihe
GB982737A (en) * 1961-05-08 1965-02-10 Westminster Bank Ltd Improvements in or relating to lysergic acid compounds
GB996062A (en) * 1961-07-13 1965-06-23 Westminster Bank Ltd Improvements in or relating to lysergic acid compounds

Also Published As

Publication number Publication date
CN1019451B (zh) 1992-12-16
AU613641B2 (en) 1991-08-08
JPS6416781A (en) 1989-01-20
KR890000482A (ko) 1989-03-14
CN1030586A (zh) 1989-01-25
NZ225022A (en) 1990-07-26
MX11866A (es) 1993-12-01
JP2653835B2 (ja) 1997-09-17
EP0296748A1 (en) 1988-12-28
ZA884222B (en) 1990-02-28
ATE87921T1 (de) 1993-04-15
SU1597103A3 (ru) 1990-09-30
HU203344B (en) 1991-07-29
IL86725A (en) 1993-01-14
EG18586A (en) 1993-08-30
CA1339661C (en) 1998-02-10
PH24309A (en) 1990-05-29
HUT47271A (en) 1989-02-28
IE881788L (en) 1988-12-15
HK77693A (en) 1993-08-13
UA6022A1 (uk) 1994-12-29
PT87716A (pt) 1988-07-01
IE61884B1 (en) 1994-11-30
DE3880022T2 (de) 1993-08-19
IL86725A0 (en) 1988-11-30
DE3880022D1 (de) 1993-05-13
EP0296748B1 (en) 1993-04-07
AU1765288A (en) 1988-12-15
DK322588D0 (da) 1988-06-14
KR960010454B1 (ko) 1996-08-01
PT87716B (pt) 1992-10-30
HU211235A9 (en) 1995-11-28
DK322588A (da) 1989-02-01

Similar Documents

Publication Publication Date Title
DK0378518T3 (da) Adenosinderivater med farmaceutisk aktivitet som antihypertensiva
PT918776E (pt) Sintese total de acilfulvenos antitumorais
ES2054806T3 (es) Cicloalquilamidas de (8beta)-1-alquil-6-(sustituido)-ergolinas.
ES2094772T3 (es) Derivados de imidazonaftiridinas.
HK1004750A1 (en) Bicyclic sulfonamide derivatives and their preparation their use and formulations containing them
GR3001955T3 (en) N-phenethylaminoalkyl-benzamide anti-arrhythmia agents
GR3005444T3 (es)
DK0420224T3 (da) Anthihepatopatisk middel
EP0555479A4 (es)
PT99043A (pt) Processo para a preparacao de composicoes biocidas contendo derivados de 4,5-polimetileno-4-isotiazolin-3-onas
FI901277A0 (fi) 2,5,6,7-tetranor-4,8-inter-m-fenylen pg1z-derivativ.
FI872997A (fi) Amidderivat.
FR2598914B1 (fr) Composition prophylactique et curative pour l'arteriosclerose
ES2143974T3 (es) Analogos de prostaglandina i.
ES2053808T3 (es) Nuevos compuestos azolicos.
FI821872A0 (fi) N-/2-(2-amino-2-fenyletyl)fenyl/-2,2-dimetyl-propanamid och dess derivat samt foerfarande foer derasframstaellning
ATE100449T1 (de) 1,3-dioxolan-benzoesaeure und derivate davon.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 296748

Country of ref document: ES